Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMGFTAI)

Drug Name
SHR0534 Drug Info
Indication
Disease Entry ICD 11 Status REF
Type 2 diabetes 5A11 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMGFTAI

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Free fatty acid receptor 1 (GPR40) TTB8FUC FFAR1_HUMAN Agonist [2]
Inflammation-related GPCR EX33 (GPR84) TTG0MQD GPR84_HUMAN Agonist [2]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 05 Endocrine, nutritional or metabolic disease
Disease Class ICD-11: 5A11 Type 2 diabetes mellitus
The Studied Tissue Liver tissue
The Studied Disease Type 2 diabetes [ICD-11:5A11]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Free fatty acid receptor 1 (GPR40) DTT FFAR1 6.14E-01 -0.08 -1.33
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03006159) A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients. U.S. National Institutes of Health.
2 Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75.